Buchumschlag

ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: survival and long-term safety

Objective - To evaluate secondary efficacy endpoints and safety for the ENGOT-OV16/NOVA (NCT01847274) trial of niraparib maintenance therapy after extended follow-up and vital-status-data retrieval. Previously reported analyses (data cutoff, October 1, 2020) indicated benefit of niraparib maintenanc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Matulonis, Ursula A. (VerfasserIn) , Herrstedt, Jørn (VerfasserIn) , Oza, Amit (VerfasserIn) , Mahner, Sven (VerfasserIn) , Redondo, Andrés (VerfasserIn) , Berton, Dominique (VerfasserIn) , Berek, Jonathan S. (VerfasserIn) , Haslund, Charlotte A. (VerfasserIn) , Marmé, Frederik (VerfasserIn) , González-Martín, Antonio (VerfasserIn) , Bécourt, Stéphanie (VerfasserIn) , Tinker, Anna V. (VerfasserIn) , Ledermann, Jonathan A. (VerfasserIn) , Benigno, Benedict (VerfasserIn) , Lindahl, Gabriel (VerfasserIn) , Colombo, Nicoletta (VerfasserIn) , Malinowska, Izabela A. (VerfasserIn) , Liu, Wenlei (VerfasserIn) , Bains, Manjinder (VerfasserIn) , Monk, Bradley J. (VerfasserIn) , Mirza, Mansoor R. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: April 2025
In: Gynecologic oncology
Year: 2025, Jahrgang: 195, Pages: 192-199
ISSN:1095-6859
DOI:10.1016/j.ygyno.2025.03.018
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ygyno.2025.03.018
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0090825825000873
Volltext
Verfasserangaben:Ursula A. Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo, Dominique Berton, Jonathan S. Berek, Charlotte A. Haslund, Frederik Marmé, Antonio González-Martín, Stéphanie Bécourt, Anna V. Tinker, Jonathan A. Ledermann, Benedict Benigno, Gabriel Lindahl, Nicoletta Colombo, Izabela A. Malinowska, Wenlei Liu, Manjinder Bains, Bradley J. Monk, Mansoor R. Mirza
Beschreibung
Zusammenfassung:Objective - To evaluate secondary efficacy endpoints and safety for the ENGOT-OV16/NOVA (NCT01847274) trial of niraparib maintenance therapy after extended follow-up and vital-status-data retrieval. Previously reported analyses (data cutoff, October 1, 2020) indicated benefit of niraparib maintenance therapy beyond first progression, but overall survival (OS) analyses were limited by missing data. - Methods - Patients were randomized 2:1 to niraparib (300mg once daily) or placebo. A vital status check was extended to retrieve last-known-alive status for patients with missing survival data. Prespecified secondary efficacy outcomes (OS, chemotherapy-free interval [CFI], time to first subsequent therapy [TFST], PFS2, time to second subsequent therapy [TSST]) and safety are reported based on the extended data cutoff (March 31, 2021). - Results - Survival status was available for 97.6% (540/553) of randomized patients (germline BRCA [gBRCA]-mutated, 203; non-gBRCA-mutated, 350). Median OS with niraparib and placebo was 40.9 and 38.1months, respectively, in the gBRCA-mutated cohort (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.61-1.20) and 31.0 and 34.8months, respectively, in the non-gBRCA-mutated cohort (HR, 1.06; 95% CI, 0.81-1.37). Medians for CFI, TFST, PFS2, and TSST numerically favored niraparib in both cohorts. No new safety signals were detected. - Conclusions - OS did not significantly differ between treatment arms. Prespecified secondary efficacy endpoints numerically favored niraparib. Long-term safety remained consistent with the established niraparib safety profile. Taken together with the significant improvements in PFS observed in the primary analysis, these data support a favorable overall benefit-risk profile for niraparib in the recurrent OC maintenance setting.
Beschreibung:Online veröffentlicht: 25. März 2025, Artikelversion: 25. März 2025
Gesehen am 23.06.2025
Beschreibung:Online Resource
ISSN:1095-6859
DOI:10.1016/j.ygyno.2025.03.018

Ähnliche Einträge